Melanotan II

The first paragraph on most peptide pages summarises the molecule's pharmacology and intended use. The first paragraph on this one summarises a regulatory record. The FDA, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency, and the Australian Therapeutic Goods Administration have each, independently, issued public-facing safety warnings about products marketed as melanotan or melanotan II — concerns are consistent across jurisdictions and include unverified product identity in the gray-market supply, melanocytic-lesion changes including documented melanoma cases, transient blood-pressure and sympathomimetic effects severe enough to require emergency-department care, priapism, rhabdomyolysis with secondary renal injury, and persistent hyperpigmentation in lips, gingiva, palms, and pre-existing nevi. Melanotan II is not approved as a medicine anywhere. The "Barbie drug" framing in popular coverage understates the case-report literature; what follows describes what the published research shows.

The human-efficacy evidence for Melanotan II's two main effect categories is published but small. Dorr et al. 1996 demonstrated tanning in three subjects with five low-dose subcutaneous administrations. Wessells et al., J Urol 1998 ran a double-blind, placebo-controlled crossover study at 0.025 mg/kg in ten men with psychogenic erectile dysfunction: 8 of 10 produced clinically apparent erections, with mean tip-rigidity-above-80% duration of 38 minutes on Melanotan II versus 3 minutes on placebo (p=0.0045). The follow-on study, Wessells et al., Int J Impot Res 2000, 12(Suppl 4):S74-S79, pooled twenty men with psychogenic and organic ED in a crossover design and reported penile erection in 17 of 20 absent any sexual stimulation, increased sexual desire on 13 of 19 (68%) Melanotan II doses versus 4 of 21 (19%) on placebo, and severe nausea in 12.9% of subjects at the highest tested dose. The published human dataset for tanning and erectile response stops essentially there — Palatin's subsequent development migrated to bremelanotide (Diamond et al. 2004), and the parent Melanotan II compound never entered a registrational Phase II or III.

The case-report literature on harms is where the published evidence depth concentrates. Cardones and Grichnik, Arch Dermatol 2009, 145(4):441-444 reported a forty-year-old bodybuilder with prior melanoma and dysplastic-nevus syndrome who developed crops of new pigmented nevi with atypical clinical and histologic features after self-administering synthetic α-MSH peptide for competition tanning. Paurobally et al., Br J Dermatol 2011, 164(6):1403-1405 reported a forty-two-year-old woman whose abdominal naevus showed suspicious enlargement and colour change over three months after Melanotan II self-injection, with histology confirming melanoma. Hjuler and Lorentzen, Dermatology 2014, 228(1):34-36 reported a twenty-year-old woman with cutaneous melanoma three months after a three-to-four-week course of Melanotan II combined with sunbed use. Nelson, Bryant, and Aks, Clin Toxicol 2012, 50(10):1169-1173 reported a thirty-nine-year-old man who presented two hours after subcutaneously injecting 6 mg of internet-sourced Melanotan II with sympathomimetic excess, rhabdomyolysis (peak creatine kinase 17,773 IU/L), and acute kidney injury requiring intensive-care fluid resuscitation. Peters et al., CEN Case Reports 2020, 9(2):159-161 reported renal infarction affecting roughly half of one kidney after cumulative Melanotan II exposure of 27 mg over six months. Bonchev, Life 2026, 16(2):265 reported persistent gingival hyperpigmentation at three-month follow-up after a 64-day course. The narrative reviews — Langan, Nie, and Rhodes, Br J Dermatol 2010, 163(3):451-455 on the "Barbie drug" gray-market landscape, and Habbema et al., Int J Dermatol 2017, 56(10):975-980 on the risks of unregulated α-MSH analog use — collate the case literature and frame the regulatory posture.

The honest framing has four parts. First, the pharmacology of tanning and sexual response is real, and the spin-off molecules (afamelanotide for EPP, bremelanotide for HSDD) inherit and successfully redirect it at receptor-selective doses. Second, the trial-grade evidence for Melanotan II itself is almost nonexistent beyond the late-1990s pilots — the development effort migrated to the receptor-selective descendants explicitly because the pan-melanocortin profile was unfavourable. Third, the case-report literature for serious harms is substantial: melanoma across multiple independent dermatology groups, dysplastic-nevus eruptions, priapism, rhabdomyolysis, renal infarction, persistent mucosal and palm-and-lip hyperpigmentation. Case reports do not establish causation by themselves, but the convergence across independent groups, the mechanistic plausibility, and the parallel regulator response (FDA, EMA, MHRA, TGA each warning independently) together produce an unusually consistent unfavourable signal. Fourth, each gray-market indication has a properly-developed alternative: afamelanotide for the rare medical contexts in which MC1R-driven pigmentation is therapeutic; PT-141 for sexual function with the trial scaffolding documented in the sexual function decision guide. The WADA prohibited-status registry covers the doping-control implications.

The Melanotan I / Melanotan II distinction is regularly confused in gray-market marketing. Melanotan I — afamelanotide — is a linear thirteen-residue α-MSH analog with MC1R-preferential affinity, holds an EMA marketing authorization (2014) and FDA approval (2019) as Scenesse for erythropoietic protoporphyria, and is administered as a sustained-release implant under clinical supervision. Melanotan II is the cyclic heptapeptide described above, with pan-melanocortin binding, no marketing authorization anywhere, and the case-report profile discussed. Products sold online as "melanotan" without further specification are almost always Melanotan II.